“Edison’s accessible and high-quality research gives us the opportunity to communicate an independent perspective of Tyman to a wide variety of potential stakeholders.”
Currency in USD
Last close As at 28/03/2023
USD1.86
▲ −0.28 (−13.08%)
Market capitalisation
USD27m
Immix Biopharma’s lead asset, IMX-110, is being investigated in a Phase Ib/IIa study for the treatment of soft tissue sarcoma and a Phase Ib trial in advanced solid tumors in combination with the ICI tislelizumab. Immix also has a pre-clinical pipeline based on the TSTx technology.
With IMX-110 Immix is targeting the STS market, a rare cancer with c 13,000–16,000 new cases reported in the United States each year and limited safe and effective treatment options. IMX-110’s combination study may further expand the drug’s offering into new indications.
Managing Director - Head of Content, Healthcare
Dr Ilya Rachman
CEO
Gabriel Morris
CFO
Forecast net debt (US$m)
15.1
Forecast gearing ratio (%)
N/A
| % | 1M | 3M | 12M |
|---|---|---|---|
| Actual | (13.1) | (7.0) | (12.7) |
| Relative | (13.0) | (10.5) | (0.3) |
| 52 week high/low | US$3.1/US$0.8 |
Immix Biopharma has announced additional data from the ongoing Phase Ib/II open-label NEXICART-1 trial investigating the company’s CAR-T therapy, NXC-201, for the treatment of multiple myeloma (MM) and light chain amyloidosis (ALA). The latest data from the study are related to a subset of the trial population with ALA (n=8) in which all patients have demonstrated a 100% complete hematologic response and 100% organ response rate. NXC-201 also continues to demonstrate a favorable safety profile, which management believes provides the therapy with potential to be used as an outpatient treatment. In our view, this could be an advantage compared to existing CAR-T therapies, which require specialized dosing centers and diligent patient monitoring post treatment.
| Y/E Dec | Revenue (US$m) | EBITDA (US$m) | PBT (US$m) | EPS (c) | P/E (x) | P/CF (x) |
|---|---|---|---|---|---|---|
| 2020A | 0.0 | (0.5) | (0.6) | (50.88) | N/A | N/A |
| 2021A | 0.0 | (1.4) | (1.3) | (35.91) | N/A | N/A |
| 2022E | 0.0 | (6.2) | (5.9) | (42.56) | N/A | N/A |
| 2023E | 0.0 | (8.8) | (8.8) | (63.12) | N/A | N/A |
